To assess the anti-pancreatic cancer effect of dFdC and c-Myc inhibitors (10,058-F4 and 10,074-G5), we initially examined the cell viability in pancreatic cancer Panc-1 and Mia-Paca cells. The gene discussed is MYC; the disease is familial pancreatic carcinoma.